Loading…
Industrial Finance Corporation Act
Legislative Progress
Introduced
August 5, 2021
Latest Action
August 5, 2021
Primary Sponsor
Christopher A. CoonsDemocratic(DE)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Industrial Finance Corporation Act This bill establishes within the executive branch the Industrial Finance Corporation. The corporation must provide support for (1) manufacturing and supply chains in certain critical industries, (2) industries on the technological frontier, and (3) other economic objectives. The bill specifies the membership and structure of the corporation and authorizes the corporation to invest in projects, make loans, and manage programs to further the corporation's economic objectives. The corporation also has the power to purchase or lease property, enter contracts, borrow funds from the Department of the Treasury (up to a specified limit), and otherwise carry out its functions. A risk committee must develop and review the corporation's risk management policies and an audit committee must oversee the integrity of the corporation's finances. The bill also requires the corporation to develop a performance measurement system to evaluate and monitor projects and guide future projects. Further, the corporation must develop appropriate safeguards, policies, and guidelines to ensure that its projects supplement, rather than compete with, private sector supports. The corporation must periodically report on its projects and publish certain project-level information.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
S.3015 - Telework Reform Act of 2024 S.4043 - Telework Transparency Act Nomination of Karla Campbell to Sixth Circuit Court of Appeals FLRA Nomination H.R.6276 - USE IT Act of 2023 H.R.4186 - Patriotic Corporations of America Act of 2021 S.2662 - Industrial Finance Corporation Act Nomination of Mustafa Kasubhai to the United States District Court for the District of Oregon.
Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $620,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Economics/Economic Development
Efforts related to the Industrial Finance Corporation Act, S. 2662, and companion house version. Bill would create a government finance corporation that would invest in emerging technologies, strengthen supply chain resilience, and other sectors critical to national security and economic competitiveness. Efforts relating to the strengthening of the Development Finance Corporation's equity authority. Advocacy for the creation of commodity reserves to help increase investment and stabilize prices.
Client expense: Not reported · Firm income: Not reported
Government targets: SENATE
2023 · third_quarter · Economics/Economic Development
Efforts related to the Industrial Finance Corporation Act, S. 2662, and companion house version. Bill would create a government finance corporation that would invest in emerging technologies, strengthen supply chain resilience, and other sectors critical to national security and economic competitiveness. Efforts relating to the strengthening of the Development Finance Corporation's equity authority. Advocacy for the creation of commodity reserves to help increase investment and stabilize prices.
Client expense: $20,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
2023 · second_quarter · Economics/Economic Development
Efforts related to the Industrial Finance Corporation Act, S. 2662, and companion house version. Bill would create a government finance corporation that would invest in emerging technologies, strengthen supply chain resilience, and other sectors critical to national security and economic competitiveness. Prepared materials for offices to assist with Humphrey-Hawkins hearings pertaining to the Federal Reserve's inflation framework. Advocated for the creation of commodity reserves to help increase investment and stabilize prices. Advocated for appointment of Julia Coronado and Seth Carpenter to be nominated Vice Chair of the Federal Reserve. Efforts related to reforming permitting for energy and other major Federal projects.
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
2023 · first_quarter · Economics/Economic Development
Efforts related to the Industrial Finance Corporation Act, S. 2662, and companion house version. Bill would create a government finance corporation that would invest in emerging technologies, strengthen supply chain resilience, and other sectors critical to national security and economic competitiveness. Prepared materials for offices to assist with Humphrey-Hawkins hearings pertaining to the Federal Reserve's inflation framework. Advocated for the creation of commodity reserves to help increase investment and stabilize prices. Advocated for appointment of Julia Coronado to be nominated Vice Chair of the Federal Reserve.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
2022 · fourth_quarter · Economics/Economic Development
Efforts related to the Industrial Finance Corporation Act, S. 2662, and companion house version. Bill would create a government finance corporation that would invest in emerging technologies, strengthen supply chain resilience, and other sectors critical to national security and economic competitiveness.
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Drug Pricing Reform Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections and American Made preferences HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act, ASP+8 H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act H.R. 7400 /S. 3991 American Made Pharmaceuticals Act Biosimilar Patient and Provider Education (including Part D) FDA foreign inspections S. 3799 PREVENT Pandemics Act ASPR/BARDA funding and policy H.R. 2870 Essential Medicine Strategic Stockpile Act (EMSSA) H.R. 5376 Inflation Reduction Act
Client expense: $275,000 · Firm income: Not reported
2022 · third_quarter · Economics/Economic Development
Efforts related to the United States Innovation and Competition Act, and the House Companion America COMPETES Act, to establish a program of supply chain resilience. Efforts related to combating inflation, particularly emphasizing health care policies that would have a disinflationary impact. Efforts related to the Industrial Finance Corporation Act, S. 2662, and companion house version. Bill would create a government finance corporation that would invest in emerging technologies, strengthen supply chain resilience, and other sectors critical to national security and economic competitiveness. Prepared materials for offices to assist with Humphrey-Hawkins hearings pertaining to the Federal Reserve's inflation framework and hearings pertaining to Federal Reserve and Department of Treasury's response to the COVID-19 crisis. Assisted in development of proposal to create automatic stabilizer program for state and local government funding.
Client expense: $50,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
2022 · third_quarter · Health Issues
Build Back Better Act Drug Pricing Reform ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections and American Made preferences HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act H.R. 7400 /S. 3991 American Made Pharmaceuticals Act Biosimilar Patient and Provider Education (including Part D) FDA foreign inspections S. 3799 PREVENT Pandemics Act ASPR/BARDA funding and policy H.R. 2870 Essential Medicine Strategic Stockpile Act (EMSSA) H.R. 5376 Inflation Reduction Act
Client expense: $250,000 · Firm income: Not reported
2022 · second_quarter · Economics/Economic Development
Efforts related to the United States Innovation and Competition Act, and the House Companion America COMPETES Act, to establish a program of supply chain resilience. Efforts related to combating inflation, particularly the emphasizing health care policies that would have a disinflationary impact. Efforts related to the Industrial Finance Corporation Act, S. 2662, and companion house version. Bill would create a government finance corporation that would invest in emerging technologies, strengthen supply chain resilience, and other sectors critical to national security and economic competitiveness. Prepared materials for offices to assist with Humphrey-Hawkins hearings pertaining to the Federal Reserve's inflation framework and hearings pertaining to Federal Reserve and Department of Treasury's response to the COVID-19 crisis. Assisted in development of proposal to create automatic stabilizer program for state and local government funding.
Client expense: $50,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
2022 · second_quarter · Health Issues
Build Back Better Act Drug Pricing Reform ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act American Made Pharmaceutical Act
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2022 · first_quarter · Economics/Economic Development
Efforts related to the United States Innovation and Competition Act, and the House Companion America COMPETES Act, to establish a program of supply chain resilience. Efforts related to accelerating the widespread adoption of 5G technology. Efforts related to the Industrial Finance Corporation Act, S. 2662, and companion house version; bill would create a government finance corporation that would invest in emerging technologies, strengthen supply chain resilience, and other sectors critical to national security and economic competitiveness. Prepared materials for offices to assist with Humphrey-Hawkins hearings pertaining to the Federal Reserve's inflation framework and hearings pertaining to Federal Reserve and Department of Treasury's response to the COVID-19 crisis.
Client expense: $50,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
2022 · first_quarter · Health Issues
Build Back Better Act Drug Pricing Reform ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act American Made Pharmaceutical Act
Client expense: $200,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2021 · fourth_quarter · Health Issues
Build Back Better Act Drug Pricing ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Pass Through Status Extension Appropriations and reach out pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake 340B Drug Pricing Program American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, White House Office
2021 · fourth_quarter · Economics/Economic Development
Efforts related to combating inflation, particularly the emphasizing health care policies that would have a disinflationary impact. Efforts related to the Industrial Finance Corporation Act, S. 2662, and companion house version. Bill would create a government finance corporation that would invest in emerging technologies, strengthen supply chain resilience, and other sectors critical to national security and economic competitiveness. Prepared materials for offices to assist with Humphrey-Hawkins hearings pertaining to the Federal Reserve's inflation framework and hearings pertaining to Federal Reserve and Department of Treasury's response to the COVID-19 crisis. Assisted in development of proposal to create automatic stabilizer program for state and local government funding.
Client expense: $50,000 · Firm income: Not reported
Government targets: Council of Economic Advisers (CEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
2021 · third_quarter · Health Issues
S.164 - Advancing Education on Biosimilars Act of 2021 Pass-Through Status Extension Medicare payments for Biosimilars Appropriations and reach out pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake 340B Drug Pricing Program American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, White House Office
2021 · third_quarter · Financial Institutions/Investments/Securities
Issues relating to exemptions from the proxy rules for proxy voting advice (Re. No. 34-89372); issues relating to procedural requirements and resubmission thresholds under Exchange Act Rule 14a-8 (Rel. No. 34-89963); issues relating to the Securities and Exchange Commission Request for Comment on Climate Disclosures; H.R. 4618 - Short Sale Transparency and Market Fairness Act (all provisions); H.R. ____ Commercial Credit Rating Reform Act of 2021 (all provisions); issues relating to the S. 2662 Industrial Finance Corporation Act of 2021 (workforce and labor elements of the bill).
Client expense: $11,840,000 · Firm income: Not reported
2021 · third_quarter · Economics/Economic Development
Efforts related to combating inflation, particularly the emphasizing health care policies that would have a disinflationary impact. Efforts related to the Industrial Finance Corporation Act, S. 2662, and companion house version. Bill would create a government finance corporation that would invest in emerging technologies, strengthen supply chain resilience, and other sectors critical to national security and economic competitiveness. Prepared materials for offices to assist with Humphrey-Hawkins hearings pertaining to the Federal Reserve's inflation framework and hearings pertaining to Federal Reserve and Department of Treasury's response to the COVID-19 crisis. Assisted in development of proposal to create automatic stabilizer program for state and local government funding.
Client expense: $40,000 · Firm income: Not reported
Government targets: Council of Economic Advisers (CEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
| Democratic |
| VA |
| Michael F. Bennet | Democratic | CO |
| Raphael G. Warnock | Democratic | GA |
| Tammy Baldwin | Democratic | WI |
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)